Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab Myasthtenia ...
Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback